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Abstract
Background: Uveal melanoma patients with a poor prognosis can be detected through genetic analysis of the
tumor, which has a very high sensitivity. A large number of patients with uveal melanoma decide to receive
information about their individual risk and therefore routine prognostic genetic testing is being carried out on a
growing number of patients. It is obvious that a positive prediction for recidivism in the future will emotionally
burden the respective patients, but research on the psychosocial impact of this innovative method is lacking.
The aim of the current study is therefore to investigate the psychosocial impact (psychological distress and
quality of life) of prognostic genetic testing in patients with uveal melanoma.
Design and methods: This study is a non-randomized controlled prospective clinical observational trial.
Subjects are patients with uveal melanoma, in whom genetic testing is possible. Patients who consent to genetic
testing are allocated to the intervention group and patients who refuse genetic testing form the observational
group. Both groups receive cancer therapy and psycho-oncological intervention when needed. The psychosocial
impact of prognostic testing is investigated with the following variables: resilience, social support, fear of tumor
progression, depression, general distress, cancer-specific and general health-related quality of life, attitude towards
genetic testing, estimation of the perceived risk of metastasis, utilization and satisfaction with psycho-oncological
crisis intervention, and sociodemographic data. Data are assessed preoperatively (at initial admission in the clinic)
and postoperatively (at discharge from hospital after surgery, 6–12 weeks, 6 and 12 months after initial admission).
Genetic test results are communicated 6–12 weeks after initial admission to the clinic.
Discussion: We created optimal conditions for investigation of the psychosocial impact of prognostic genetic
testing. This study will provide information on the course of disease and psychosocial outcomes after prognostic
genetic testing. We expect that empirical data from our study will give a scientific basis for medico-ethical
considerations.
Keywords: Uveal melanoma, Genetic testing, Psychological distress, Quality of life, Psycho-oncology, Resilience,
Social support, Shared decision-making
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Background
There are two tumor-biological classes of uveal melan-
oma, which differ markedly from each other concerning
the risk of metastasis [1, 2]. Both tumor classes can be
determined either through detection of monosomy 3 in
tumor DNA [1], or by a multi-gene expression profile of
tumor RNA [2]. Due to the tumor class, the risk of de-
veloping metastases varies pronouncedly: In a current
study [3], the mortality rates due to metastasis were
13.2 % for tumors with disomy 3 and 75.1 % for tumors
with monosomy 3 (median follow-up time of 5.2 years).
Generally, it was found that global quality of life was
significantly reduced in patients with malignant uveal
melanoma (compared to the healthy norm and other
ophthalmological patients, both pre and post treatment),
with one half of patients displaying clinically relevant
distress pre treatment and one third post treatment [4].
More recent studies concerning quality of life have
revealed different improvements and deteriorations after
treatment of uveal melanoma: significant decrease of
physical functioning and physical role, but on the other
hand significant improvement of mental health [5];
furthermore decreases in social functioning, but also in
anxiety levels [6].
Prognostic testing of monosomy 3 in uveal melanoma
patients aims at determinating the risk of metastasis in
patients who have already been diagnosed with cancer.
However, (until now) genetic testing does not directly
affect treatment decisions [7]. This is in contrast to most
of the studies targeting the psychosocial impact of prog-
nostic genetic testing, which are performed with persons
at risk for familial cancer (hereditary risk), but not yet
diseased. Investigating uveal melanoma patients
broadens this field by examining patients who have to
decide whether they want to receive very reliable infor-
mation about their future (prognosis and life perspec-
tive), while already being affected with cancer. Due to
the dichotomous outcome (disomy 3 = good prognosis,
monosomy 3 = poor prognosis), we assume patients to
have high levels of involvement and psychological
distress. Comparably, a positive test for a predisposition
to breast cancer causes psychological reactions similar to
those after a manifest diagnosis [8].
In relation to this, additional questions arise concern-
ing patient autonomy and decision making. Concerning
the psychological impact of prognostic genetic testing in
patients with uveal melanoma, three studies could be
identified: In a retrospective study, patients wanted
prognostic information even though they were informed
that medical care would not be influenced by the result.
Furthermore, depressive symptoms and quality of life
were found to be independent of a positive test result
[9]. Another research group did not find any patients
having regrets about prognostic diagnostics (even in the
case of poor prognosis) and therefore concluded that
there were no harmful effects of the diagnostic testing
[10]. In another prospective study [11], patients often
did not seem to realize they had to make a decision, for
prognostic genetic testing was part of “normal” treat-
ment for them – patients utilized the test because they
trusted in what their physicians offered them. The
authors concluded that active decision-making and con-
sent procedures are not realistic in acute clinical situa-
tions. They even further stated that protecting patients’
interests is the physicians’ responsibility and not deleg-
able to patients.
Moreover, two important issues have to be noted:
First, only few respondents strive for an autonomous
role in the decision-making process, as often a passive
role (particularly in older and less educated patients) is
preferred [12]. Second, cancer risks and heredity
likelihood were often perceived inaccurately by the
counselees. Outcomes like quality of life or current
psychological wellbeing could therefore not be predicted
by the actually communicated cancer risk, but were
mainly mediated or predicted by perceived risk [13].
This might also counteract informed decision-making.
Another important issue is the question of which indi-
viduals take the opportunity of genetic testing and/or
counseling and which individuals do not (different
motivating factors). In a sample of colorectal cancer
patients, nonmetastatic cancer, lower perceived risk for
cancer recurrence, and greater self-efficacy were associ-
ated with greater perceived benefits – whereas perceived
barriers were related to cancer-specific psychological dis-
tress. Generally, individuals considering the test have
positive attitudes towards it and perceive few barriers
[14]. Furthermore, the following factors were found to
be related to the decision to utilize genetic testing for
BRCA 1/2: personal history of cancer, perceiving more
benefits than barriers concerning genetic testing, having
greater family hardiness, and perceiving a breast cancer
diagnosis as associated with fewer negative conse-
quences [15]. Other common motivations for the
utilization of prognostic genetic testing are use of more
screening offers, reassurance, and taking care of oneself
([16]; breast cancer screening).
Study aims
The objective of this study is to investigate the psycho-
social impact (psychological distress and quality of life)
of prognostic genetic testing in patients with uveal
melanoma.
This comprises three main issues:
1) Decision-making: Which patients utilize genetic
testing? What attitudes predominate in these
patients? For this purpose we ask patients about
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their attitudes towards genetic testing, perceived
risk, social support, and sociodemographic data.
2) Psychological distress: How distressing is genetic
testing? Should psychological interventions be
implemented to reduce pronounced psychological
distress? To measure this, we investigate distress
and record which patients utilize psycho-oncological
interventions.
3) Risk: Which patients are at risk for pronounced
psychological distress? To answer this question,
we assess resilience, social support, and fear of
progression as moderating factors of mental health
and stability.
A prospective study is being conducted to investigate
(possibly different) trajectories of disease between
patients undergoing and not undergoing prognostic gen-
etic testing. In particular, it is possible to examine
whether and how patients benefit from knowing the
prognosis, even though no medical decisions depend on
the test results. These findings should be included in
future informed consent. Furthermore, we will be able to
overcome shortcomings of previous studies in this field,
namely retrospectivity [9], a qualitative approach and
small sample sizes [10, 11].
Hypotheses
1) Sociodemographic and psychological features will
moderate the utilization of prognostic genetic
testing: Patients with high education, high social
support, high resilience, and a previous history of
cancer will utilize genetic testing more often than
patients with low levels of education, or low social
support, or a previous history of cancer.
2) Attitudes towards prognostic testing (attitude scale)
will remain stable between the measurement points.
Patients with a positive attribution towards genetic
testing will give their consent to it more often.
3) Perceived risk of metastasis will change after
disclosure of the test result. In approximately 50 %
of the patients, individually perceived risk and the
objective result of the test will be congruent
(congruency means that patients understood the
communicated information).
4) Psychological variables will change after prognostic
testing and in the further trajectory of the disease:
a) At T1 (initial admission to the clinic, diagnosis),
psychological distress levels of patients with uveal
melanoma will be significantly increased
compared to a norm sample – irrespective of
whether they gave their consent to genetic testing
(intervention group; IG) or not (observational
group; OG).
b) At T2 (day of discharge after surgery),
IG-patients and OG-patients will not differ
concerning psychological distress, but distress
levels will be increased compared to T1 and
compared to a norm sample.
c) At T3 (communication of the result, 6–12 weeks
after surgery), IG-patients with poor prognosis
(IGpp) will have the highest levels of psycho-
logical distress and the lowest mental quality of
life compared to IG-patients with good prognosis
(IGgp) and OG-patients. IPgp-Patients will have
the lowest psychological distress and the highest
mental quality of life and will be comparable to a
norm sample.
d) At T4 (6 months after initial admission),
psychological distress in IGpp-patients will be
significantly decreased compared to T3, but there
will still be significant group differences.
e) At T5 (12 months after initial admission),
psychological distress levels in IGpp-patients will
be further decreased, but still higher than in
IGgp-patients and in a norm sample.
5) Psycho-oncological crisis intervention:
a) Patients with a higher load of psychological
symptoms will utilize psycho-oncological
interventions more often.
b) Approximately 10 % of the patients will utilize
psycho-oncological crisis interventions.
c) Patient satisfaction is expected to be high.
Methods
Organizational structure of the study
This study is conducted within a network of three collab-
orative investigations (see Fig. 1) funded by the German
Cancer Aid. A corporate time table was developed, in
which the three projects were embedded (see Table 1).
Study population
Patients are included in the study if they are reliably
diagnosed with uveal melanoma and if removal of a
tumor sample is possible (enucleation or biopsy). Fur-
thermore, they have to be aged between 18 and 90 years,
have sufficient knowledge of the German language and
give informed consent to take part in the study. Patients
are excluded from the study if they have a pre-existing
diagnosis of mental disability, psychosis or dementia.
Recruitment
The sample of this study is a consecutive sample of
patients with uveal melanoma undergoing cancer ther-
apy in the Department of Ophthalmology of the Univer-
sity Hospital in Essen, Germany, which is a national
center for treatment of patients with ophthalmic tumors.
Therefore, more than 170 patients with a first diagnosis
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of uveal melanoma undergo prognostic genetic testing
for monosomy 3 every year.
Allocation to the study groups
This study is a non-randomized controlled prospective clin-
ical observational trial. Patients are allocated to the groups
by their choice (non-randomized) of whether to utilize
prognostic genetic testing (intervention group, IG) or not
(observationsal group, OG). Blinding is not possible.
Measurement points
Data are assessed preoperatively (at initial admission in
the clinic) and postoperatively (at discharge from hospital
after surgery, 6–12 weeks, 6 and 12 months after initial
admission); the detailed time flow of the study can be seen
in Fig. 2.
Measures assessed
Exclusively at baseline assessment (initial admission in
the clinic): sociodemographic data, medical history and
initial protective factors are recorded. For assessment of
initial protective factors (resilience and perceived social
support), participants complete the short form of the
sense of coherence scale [17], the short form of the
social support questionnaire [18] and the subscale “social
strain” from the long form of the social support ques-
tionnaire [19, 20].
Fig. 1 Organizational structure of the study network
Table 1 Corporate time table of the study network






T1 Initial admission in the clinic • Information about the 3 projects and about monosomy 3 diagnostics
• medical history (patient and familiy)
• psychometric questionnaires
Surgery (4–6 weeks after initial admission)
T2 Discharge from hospital after surgery psychometric questionnaires plasma sample
T3 6-12 weeks after surgery (IG);
8 weeks after surgery (OG)
• offer of psycho-oncological
support
• psychometric questionnaires
Disclosure of test results:
• monosomy 3
• tumor disposition
T4 6 months after initial admission psychometric questionnaires plasma sample Follow-up examinations
T5 12 months after initial admission psychometric questionnaires plasma sample Follow-up examinations
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The following measures are assessed both at baseline
and at all follow-ups: psychological distress, (general and
specific) health-related quality of life, attitude towards
genetic testing, estimation of the perceived risk of metas-
tasis and utilization of psycho-oncological interventions.
Psychological distress is measured by the Fear of Pro-
gression Questionnaire [21, 22], the Hospital Anxiety
and Depression Scale (subscale depression, HADS-D,
[23]), and the distress thermometer [24]. Specific health-
related quality of life is assessed by the EORTC Quality
of Life Questionnaire (EORTC QLQ-C30, [25]) and the
ophthalmic module of the EORTC QLQ-C30 (EORTC
QLQ-OPT 30, [26]). General health-related quality of
life is measured by the short version of the Short Form
Health Survey SF-36 (SF-12; [27]). Attitudes towards
genetic testing are assessed with a modified version of
the modified Attitudes Scale [28]. The estimation of
perceived risk of metastasis is evaluated with a visual
analogue scale (VAS), from 0 to 10. The utilization of
psycho-oncological (crisis) interventions (control vari-
able) and patient satisfaction with these interventions is
recorded with a documentation form.
Detailed information about several of these measures
is provided in the Additional file 1: Appendix. Which
measures are assessed at which measurement point can
be seen in Table 2.
Psycho-oncological crisis interventions
Patients are informed at T1 that they may utilize psycho-
oncological interventions. These crisis interventions follow
Fig. 2 Time flow, expected patient numbers per year
Table 2 Use of different measures at different assessment points
T1 T2 T3 T4 T5
Resilience ✓ - - - -
Social support ✓ - - - -
Fear of progression ✓ ✓ ✓ ✓ ✓
Distress ✓ ✓ ✓ ✓ ✓
Depression ✓ ✓ ✓ ✓ ✓
Health-related Quality of life ✓ ✓ ✓ ✓ ✓
Perceived risk ✓ ✓ ✓ ✓ ✓
Attitudes towards prognostic testing ✓ ✓ ✓ ✓ ✓
Utilization of psycho-oncological intervention - ✓ ✓ ✓ ✓
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a resource-oriented approach and are conducted by a clin-
ical psychologist specialized in psycho-oncology. Frequency
and kind of crisis intervention, as well as patient satisfac-
tion, are assessed as covariates.
Statistical analysis plan
Data will be analyzed using the software SPSS for Microsoft
Windows®. For descriptive analysis, data will be expressed
as mean values, standard deviations, and frequencies; distri-
butional characteristics of all variables will be given. To
analyze simple linear relations between variables, Pearson
correlations will be calculated. For verification/falsification
of our hypotheses (group differences), ANOVAs (post hoc:
Scheffé tests), repeated measurement ANOVAs, ANCO-
VAs, parametric tests (for independent and dependent sam-
ples) and non-parametric tests (Chi2 tests, Mann–Whitney
U-tests, Wilcoxon tests, Kruskal-Wallis tests) will be calcu-
lated (according to the respective levels of measurement
and sample sizes). For prediction of the outcome variables,
multiple regression analyses will be performed. For all tests,
a significance level of p < 0.05 is predetermined.
Power considerations and calculation of patient
attendance
Calculation of the sample size (GPower) for two-tailed t-
tests with dependent samples, effect size = 0.6, probabil-
ity of error α = 0.05, and power = 0.8 resulted in a sample
size of n = 24 per group. For two-tailed t-tests with
independent samples, the same calculation resulted in n
= 45 per group. Due to anticipation of dropouts in the
study progress, we enlarged this sample size by one
third, so the final calculation of the sample size is n = 60
per group (N = 120). For the calculation of patient
attendance see Fig. 2.
Progress
Patient recruitment started in October 2014. At the
moment, 62 patients are already taking part in the study.
For detailed information about the number of patients in
each group and at each assessment point, please see Fig. 3.
Baseline sociodemographic and disease-related data of all
IG- and OG-patients included are presented in Table 3.
Discussion
In the following sections, the psychosocial impact of genetic
counseling, decision-making processes and ethical consid-
erations concerning autonomy and communication shall be
discussed within the framework of current research.
Psychosocial impact of genetic counseling
In two meta-analyses, a significant impact of genetic
counseling for familial cancer on anxiety (reduction), and
on accuracy of perceived risk and knowledge (both im-
proved) was found, suggesting genetic counseling had no
adverse psychological effects [29, 30]. Comparably, benefi-
cial effects of multidisciplinary genetic risk counseling for
familial colorectal cancer on psychosocial outcome were
found: General anxiety, familial cancer-specific distress
and general cancer worries were significantly reduced after
genetic counseling [31]. Moreover, distress and depression
levels were reduced within the first 6 months after coun-
seling and testing [32], and intrusion and avoidance
significantly reduced over time [33]. Furthermore, the
authors found passive and palliative coping styles, exces-
sive breast self-examination, and overestimation of breast
cancer risk to be predictive of increased long-term
distress. In contrast, decreased long-term distress could
be predicted by promoting reassuring thoughts.
When comparing carriers and non-carriers, carriers
were found to be significantly more distressed from test-
ing and to report increased risk perception levels and
surveillance (up to four years) [34]. Furthermore, Meiser
(2005) [35] differentiated in their review between indi-
viduals having never been affected by cancer and indi-
viduals affected by cancer. In the former condition, non-
carriers psychologically benefitted significantly, whereas
carriers experienced no adverse effects. In individuals af-
fected with cancer, the individual former cancer experi-
ence seemed to influence the effects of genetic testing.
While waiting for disclosure of the test result, acute
anxiety may emerge [36]. Phelps et al. (2013) [37] inves-
tigated the effectiveness of a self-help coping interven-
tion in patients awaiting their genetic result. Intrusive
thoughts during the waiting period could be reduced sig-
nificantly in patients with moderate baseline levels of in-
trusion. Furthermore, distress levels were decreased in
patients with low or moderate intrusive worries at base-
line. Yet, no intervention effect on the sample as a whole
could be demonstrated, suggesting that patients with
clinically high levels of psychological distress might need
more intensive psychological treatments. The authors
conclude that their intervention could provide help
while waiting for test results and feeling uncertain, in
various oncological patient groups. Moreover, there
seem to be no harmful effects on those patients that are
likely to not benefit from the intervention.
Our study was designed to investigate if these findings
could also account for uveal melanoma patients (who
have already been diagnosed with cancer).
Decision-making
Affected persons have to weigh the pros and cons of
genetic testing when making their decision. Pros are, for ex-
ample, relief from uncertainty, adjustment of important life
decisions and life planning, as well as making decisions
about intensified prophylaxis and screening programs. Cons
are, for example, risks of persistent psychological distress,
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such as depressive rumination about one’s individual risk of
disease.
It is an important ethical issue, as to how decision-
making concerning genetic testing can be improved, such
as through educative interventions both for patients and
for medical staff. Wakefield et al. (2008) [38] developed a
decision aid intervention (specifically for informed deci-
sion making concerning genetic testing for hereditary
non-polyposis colorectal cancer risk) and tested its effi-
cacy in a randomized controlled trial. Participants of the
intervention group experienced less decisional conflict
and were better informed and therefore had a better
chance of making an informed decision with regard to
genetic testing. Furthermore, Ilic et al. (2015) [39] (review,
prostate cancer) found improvements in knowledge,
reduction in decisional conflict and an increase in deci-
sional satisfaction after utilization of a decision aid inter-
vention. Moreover, Dieng et al. (2014) [40] (review, mainly
breast cancer studies) found changes in risk perception
level and accuracy after educational interventions in
prospective observational studies (n = 28), but not in ran-
domized controlled trials (n = 12). We expect our study to
shed further light on questions concerning the influence
of decision for or against genetic testing.
Ethical considerations: Autonomy and communication
Another important research question is the appropriate
and correct ethical conduct with information. The right of
self-determination and respect for the personal autonomy
of the patient form the ethical and legal basis for the
demand for information and participation in medical
decisions. It is important to note, that the right of self-
determination includes also the right of not being in-
formed, because negatively appraised health-related infor-
mation can cause severe psychological distress. So, apart
from the ethical principle of autonomy, the principles of
Fig. 3 Study flowchart
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non-maleficence and beneficence have to be taken into
account for medico-ethical analyses [41]. To minimize
psychosocial distress due to prognostic genetic testing,
genetic counseling before and directly after communica-
tion of the results is recommended by the guidelines of the
German Medical Association [42]. This recommendation
was taken into account in the elaboration of the German
Genetic Diagnostics Act. In a systematic review (93 stud-
ies), it was found that most studies about communication
of prognosis to cancer patients were conducted in early
stages of disease [43]. It remained uncertain which
approach of communication would be the best. We expect
our study to provide further information about patient
autonomy and disclosure of test results.
Limitations
There are two limitations of our study. First, randomization
and blinding is not possible. Second, patients receive differ-
ent cancer treatments (see Table 3), which might cause
differences concerning the psychosocial impact of genetic
testing. On the other hand, no differences concerning qual-
ity of life, psychological distress, depression and anxiety
were found between enucleation and radiotherapy patients
or between patients receiving different methods of radio-
therapy [44, 45].
Conclusion
We created optimal conditions for the investigation of the
psychosocial impact of prognostic genetic testing and the
course of disease, in uveal melanoma patients. The natur-
alistic design we chose is very suitable for research in the
clinical setting, but takes time and effort. We therefore
thank the German Cancer Aid for promoting this network
of three parallelized collaborative studies from different
scientific disciplines, giving the opportunity to investigate
uveal melanoma patients from different points of view.
We expect that our findings will be transferable to
other oncological entities and clinical syndromes.
Furthermore, we expect that empirical data from our
study will contribute to the continuing medico-ethical
debate on prognostic genetic testing, in the light of
patient autonomy and decision-making processes.
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Table 3 Baseline sociodemographic and disease-related characteristics of patients to date




Age in years mean ± sd: 60.03 ± 12.41 mean ± sd: 62.96 ± 12.30
range: 37–78 range: 40–82
Sex female: 16 female: 11
male: 19 male: 16
Nationality German: 34 German: 26
Polish: 1 Dutch: 1
Disease-related
characteristics
Treatment brachytherapy: 32 brachytherapy: 14
endoresection: 0 endoresection: 4
endoresection and Gamma-Knife: 1 endoresection and Gamma-Knife: 1
cyber-Knife: 0 cyber-Knife: 1
enucleation: 2 enucleation: 7
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